ArticleMedicine2025
Score-matched analysis of human papillomavirus photodynamic therapy with Nocardia rubra and aminolevulinic powder.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prediction for the Therapeutic Efficacy of Topical Nocardia Rubra Cell Wall Skeleton Human Papillomavirus Infection: A Retrospective Study.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Effective clearance of high-risk human papillomavirus (HR-HPV) and disease remission are critical in managing cervical lesions. This study compared Nocardia rubra cell wall skeleton (Nr-CWS) versus 5-aminolevulinic acid photodynamic therapy for HR-HPV clearance and lesion regression. In this single-center retrospective cohort (June 2020-May 2023), 234 patients with HR-HPV infection were assessed. After 1:1 propensity matching, 144 patients remained (72 per group). Primary and secondary endpoints were HR-HPV clearance and disease remission rates, respectively. Baseline differences in thinprep cytologic test results persisted post-matching. Nr-CWS demonstrated superior HR-HPV clearance at 6 months (76.4% vs 48.6%; P < .001) and 1 year (87.5% vs 66.7%; P = .03). Disease remission rates showed no significant differences at 6 months (72.9% vs 85.5%; P = .10) or 1 year (78.0% vs 90.9%; P = .058). Nr-CWS significantly outperformed 5-aminolevulinic acid photodynamic therapy in achieving HR-HPV clearance, while both therapies showed comparable efficacy in disease remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.